Medicinal Immunoglobulin G Products (2020) Show High Infectivity Neutralizing Activity Against Seasonal Influenza Virus Strains Selected for Future Vaccines (2020

Medicinal Immunoglobulin G Products (2020) Show High Infectivity Neutralizing Activity Against Seasonal Influenza Virus Strains Selected for Future Vaccines (2020–2022)

Published:2022-04-28 Issue:7 Volume:9 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Díez José María¹,Casals Daniel¹,Romero Carolina¹,Gajardo Rodrigo¹

Affiliation:

1. Immunotherapies Unit, Bioscience Research & Development, Scientific Innovation Office, Grifols, Barcelona , Spain

Abstract

Abstract Immunoglobulin (Ig)G medicinal products manufactured in 2020 were tested for infectivity neutralization and hemagglutination inhibition against World Health Organization-selected influenza strains included in worldwide vaccines 2020–2022. The IgG batches (from US plasma) showed potent activity. Intravenous immunoglobulin could potentially add to therapies for serious influenza cases in immunocompromised patients. Further study is warranted.

Funder

Grifols

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Link

https://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofac216/43480859/ofac216.pdf

Reference21 articles.

1. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study;Iuliano;Lancet,2018

2. Global mortality associated with seasonal influenza epidemics: new burden estimates and predictors from the GLaMOR Project;Paget;J Glob Health,2019

3. Review of global influenza circulation, late 2019 to 2020, and the impact of the COVID-19 pandemic on influenza circulation;Karlsson;WHO Wkly Epidemiol Rec,2021

4. Decreased influenza incidence under COVID-19 control measures, Singapore;Soo;Emerg Infect Dis,2020

5. Collateral benefit of COVID-19 control measures on influenza activity, Taiwan;Kuo;Emerg Infect Dis,2020